[HTML][HTML] Monitoring of acute myeloid leukemia patients after allogeneic stem cell transplantation employing semi-automated CD34+ donor cell chimerism analysis
JC Hoffmann, K Stabla, A Burchert, T Volkmann… - Annals of …, 2014 - Springer
Determination of donor chimerism profiles in blood or bone marrow from patients with
allogeneic stem cell transplantation (SCT) is useful for monitoring engraftment or predicting …
allogeneic stem cell transplantation (SCT) is useful for monitoring engraftment or predicting …
Peripheral Blood CD34 Donor Chimerism has Greater Clinical Utility Than CD3 for Detecting Relapse after Allogeneic Stem Cell Transplantation for Acute Myeloid …
TP Das, D North, SA Fleming, JLC Tan, A Ivey… - … and Cellular Therapy, 2023 - Elsevier
Monitoring of donor chimerism (DC) may detect early relapse following allogeneic
hematopoietic stem cell transplantation (allo-SCT) for acute myeloid leukemia (AML) or …
hematopoietic stem cell transplantation (allo-SCT) for acute myeloid leukemia (AML) or …
Prediction of relapse of acute myeloid leukemia in allogeneic transplant recipients by marrow CD34+ donor cell chimerism analysis
C Scheffold, M Kroeger, M Zuehlsdorf, J Tchinda… - Leukemia, 2004 - nature.com
Chimerism analysis after allogeneic hematopoietic stem cell transplantation (AHSCT)
unveils the conversion of recipient's hematopoiesis to donor type and is useful for detection …
unveils the conversion of recipient's hematopoiesis to donor type and is useful for detection …
Detection of relapse by sequential monitoring of chimerism in circulating CD34+ cells.
T Ch, K Lutterbeck, U Oelschlägel, M Kiehl… - Annals of …, 2002 - europepmc.org
Relapse of the underlying malignant disease represents one of the major causes of
treatment failure in patients treated with stem cell transplantation, especially in patients with …
treatment failure in patients treated with stem cell transplantation, especially in patients with …
Utility of assessing CD3+ cell chimerism within the first months after allogeneic hematopoietic stem‐cell transplantation for acute myeloid leukemia
M Bendjelloul, C Usureau, P Etancelin, Z Saidak… - Hla, 2022 - Wiley Online Library
After allogeneic hematopoietic stem‐cell transplantation (alloHSCT), the chimerism assay is
used to monitor cell engraftment and quantify the respective proportions of donor/recipient …
used to monitor cell engraftment and quantify the respective proportions of donor/recipient …
[HTML][HTML] Monitoring of donor chimerism in sorted CD34+ peripheral blood cells allows the sensitive detection of imminent relapse after allogeneic stem cell …
M Bornhäuser, U Oelschlaegel, U Platzbecker… - …, 2009 - ncbi.nlm.nih.gov
Abstract Analysis of donor chimerism is an important diagnostic tool to assess the risk of
relapse after allogeneic stem cell transplantation, especially in patients lacking a specific …
relapse after allogeneic stem cell transplantation, especially in patients lacking a specific …
Chimerism evaluation in measurable residual disease‐suspected cells isolated by flow cell sorting as a reliable tool for measurable residual disease verification in …
A Semchenkova, V Brilliantova… - Cytometry Part B …, 2021 - Wiley Online Library
Background The presence of minimal/measurable residual disease (MRD) before or after
hematopoietic stem cell transplantation (HSCT) is known as a predictor of poor outcome in …
hematopoietic stem cell transplantation (HSCT) is known as a predictor of poor outcome in …
Quantitative chimerism in CD3-negative mononuclear cells predicts prognosis in acute myeloid leukemia patients after hematopoietic stem cell transplantation
A Bouvier, J Riou, S Thépot, A Sutra Del Galy… - Leukemia, 2020 - nature.com
Relapse is a major complication of acute myeloid leukemia (AML) after allogeneic
hematopoietic stem cell transplantation (SCT). The objective of our study was to evaluate …
hematopoietic stem cell transplantation (SCT). The objective of our study was to evaluate …
CD34+ lineage specific donor cell chimerism for the diagnosis and treatment of impending relapse of AML or myelodysplastic syndrome after allo-SCT
F Rosenow, A Berkemeier, U Krug… - Bone marrow …, 2013 - nature.com
After allo-SCT, analysis of CD34+ lineage-specific donor cell chimerism (DCC) is a sensitive
method for monitoring minimal residual disease in patients with AML or myelodysplastic …
method for monitoring minimal residual disease in patients with AML or myelodysplastic …
Leukemia lineage-specific chimerism analysis is a sensitive predictor of relapse in patients with acute myeloid leukemia and myelodysplastic syndrome after …
J Mattsson, M Uzunel, L Tammik, J Aschan, O Ringden - Leukemia, 2001 - nature.com
One of the major complications after allogeneic stem cell transplantation (SCT) in patients
with malignant disease is a high frequency of relapse. We have prospectively analyzed the …
with malignant disease is a high frequency of relapse. We have prospectively analyzed the …